Rivaroxaban use may be associated with spontaneous subcapsular hematoma.
Rivaroxaban was approved for stroke prevention for non-valvular atrial fibrillation in 2011, with added advantage of decreased risk of bleeding in comparison to coumadin, made it a good alternative for coumadin.
No takes yet. Share an insight, caveat, or question.
Chenna et al. (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: